

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country.

Statement of Discontinuation of the study	
Name of Company: GlaxoSmithKline Biologicals	
Study No: 116763 (EudraCT# 2013-001918-15)	
Product: SB208109	
Title: A phase IV, open-label, single-centre study to assess the long-term persistence of hepatitis A antibodies in healthy adults, primed 21 to 25 years earlier with GSK Biologicals' hepatitis A vaccine Havrix (SB208109) in studies HAV-112 (208109/108) or HAV-123 (208109/114).	
Phase: IV	
Study Period: May 2015 to July 2019	
Centres: NA	
Number of Subjects: 0	
Publications: NA	
Statement on discontinuation of the study: Discontinued by GlaxoSmithKline during preparation of the trial. No patient entered the study, therefore no results / data are available.	